Trial · NCT07899697
Feasibility Study of Middle Segmental Gastrectomy (MSG) for Gastric Cancer.
NCT07899697, Not applicable, Active not recruiting, National Cancer Center, Korea
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Feasibility Study of Middle Segmental Gastrectomy (MSG) for Gastric Cancer. Trials, record NCT07899697. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07899697
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Feasibility Study of Middle Segmental Gastrectomy (MSG) for Gastric Cancer.
- NCT number
- NCT07899697
- Status
- Active not recruiting
- Phases
- Not applicable
- Enrollment
- 78 participants, estimated
- Lead sponsor
- National Cancer Center, Korea
- Conditions
- Gastric Cancer, Gastric Adenocarcinoma, Middle Segmental Gastrectomy (MSG), Function-preserving Surgery, Dumping Syndrome
- Interventions
- Totally Laparoscopic Middle Segmental Gastrectomy (TLMSG), Totally Laparoscopic Middle Segmental Gastrectomy (TLMSG)
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Dumping Syndrome at 1 Year Postoperatively (Sigstad Score ≥7) | 1 year postoperatively | Assessed using the Sigstad score questionnaire, where a total score of 7 or higher is defined as dumping syndrome (scores \< 7 indicate non-dumping) |
| Secondary | Postoperative reflux symptoms. | Preoperatively, and at 3, 12, 24, and 36 months postoperatively | Subjective reflux symptoms categorized by Visick score (Grades I-IV) and endoscopic findings of reflux esophagitis categorized by the Los Angeles (LA) classification |
| Secondary | Postoperative Changes in Nutritional Indicators | Preoperatively, and at 3, 6, 12, 18, 24, 30, and 36 months postoperatively | Nutritional status will be evaluated by assessing changes in key parameters (body weight, hemoglobin, fasting blood glucose, serum iron, vitamin B12, albumin, and total protein) measured as the percent change from preoperative baseline at each follow-up visit. Longitudinal changes from preoperative baseline through 36 months postoperatively will be analyzed using a linear mixed-effects model. Unit of Measure: Percent change from baseline (%) |
| Secondary | Incidence of Postoperative Complications | Within 30 days postoperatively (for early complications) and up to 36 months postoperatively (for late complications) | Early and late postoperative complications classified according to the Clavien-Dindo classification system and Comprehensive Complication Index (CCI) |
| Secondary | 30-Day Postoperative Mortality | Within 30 days postoperatively | Incidence of mortality occurring within 30 days of surgery |
| Secondary | Postoperative Quality of Life (QOL) | Preoperatively, and at 3, 12, 24, and 36 months postoperatively | Assessed using EORTC QLQ-C30 (functional and symptom scales) and EORTC QLQ-STO22 (gastric cancer-specific module) questionnaires |
| Secondary | 3-Year Disease-Free Survival (DFS) and Overall Survival (OS) | 3 years postoperatively | DFS (time from surgery to recurrence or death) and OS (time from surgery to death) estimated using the Kaplan-Meier method |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07899697
GET https://conductscience.org/api/trials/v1/NCT07899697/registered